US equities
|
MU
$953.19
▲+0.00%
SNDK
$1,482.33
▲+0.00%
ASML
$1,717.76
▲+0.00%
NVDA
$228.52
▲+0.00%
SKHY
$157.06
▲+0.00%
INTC
$102.81
▲+0.00%
SPCX
$156.54
▲+0.00%
AMD
$605.53
▲+0.00%
MU
$953.19
▲+0.00%
SNDK
$1,482.33
▲+0.00%
ASML
$1,717.76
▲+0.00%
NVDA
$228.52
▲+0.00%
SKHY
$157.06
▲+0.00%
INTC
$102.81
▲+0.00%
SPCX
$156.54
▲+0.00%
AMD
$605.53
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Eloxx Pharmaceuticals, Inc. - Common Stock
(NQ:
ELOX
)
12.70
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eloxx Pharmaceuticals, Inc. - Common Stock
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
April 16, 2024
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
March 13, 2024
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
November 13, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 8/30
August 30, 2023
Via
Investor Brand Network
Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) Near the Top of Equities by Percentage Gain on 4/10
April 10, 2023
Via
Investor Brand Network
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
October 09, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 19, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
September 18, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
September 07, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
August 14, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
August 14, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
August 03, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
This Small Cap Stock Surged Over 100%
July 12, 2023
Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.
Via
MarketBeat
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
July 10, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
June 28, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
June 21, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
June 21, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
June 06, 2023
Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
May 24, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
May 15, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
May 02, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
April 03, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013
March 28, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed
February 27, 2023
Topline results expected in first half of 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome
January 25, 2023
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces Reverse Stock Split Effective
December 01, 2022
ELOX common stock expected to begin trading on a split-adjusted basis on December 2, 2022
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
November 10, 2022
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome
November 01, 2022
Trial sites now open in Australia and the United Kingdom
From
Eloxx Pharmaceuticals
Via
GlobeNewswire
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
September 17, 2021
Via
FinancialNewsMedia
Topics
Death
